MEMANTINE TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

MEMANTINE HYDROCHLORIDE

Inapatikana kutoka:

SIVEM PHARMACEUTICALS ULC

ATC kanuni:

N06DX01

INN (Jina la Kimataifa):

MEMANTINE

Kipimo:

10MG

Dawa fomu:

TABLET

Tungo:

MEMANTINE HYDROCHLORIDE 10MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

100

Dawa ya aina:

Prescription

Eneo la matibabu:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0150423001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2015-10-05

Tabia za bidhaa

_ _
_MEMANTINE Product monograph _
_Page 1 of 35_
PRODUCT MONOGRAPH
PR
MEMANTINE
Memantine Hydrochloride Tablets
10 mg
N-methyl-D-aspartate (NMDA) receptor antagonist
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent, Quebec
H4R 2P7
www.sivem.ca
Date of Preparation:
March 23, 2018
Submission Control No.: 213938
_ _
_MEMANTINE Product monograph _
_Page 2 of 35_
PR
MEMANTINE
Memantine Hydrochloride Tablets
10 mg
THERAPEUTIC CLASSIFICATION
N-methyl-D-aspartate (NMDA) receptor antagonist
ACTION AND CLINICAL PHARMACOLOGY
Persistent activation of the central nervous system
N-methyl-D-aspartate (NMDA) receptors by
the excitatory amino acid glutamate has been hypothesized to
contribute to the symptomatology
of Alzheimer’s disease. Memantine is postulated to exert its
therapeutic effect through its action
as a low to moderate affinity uncompetitive (open channel) NMDA
receptor antagonist, which
binds preferentially to the NMDA receptor-operated cation channels. It
blocks the effects of
pathologically elevated sustained levels of glutamate that may lead to
neuronal dysfunction.
There is no clinical evidence that memantine prevents or slows
neurodegeneration or alters the
course of the underlying dementing process in patients with
Alzheimer’s disease. Memantine
exhibits low to negligible affinity for other receptors (GABA,
benzodiazepine, dopamine,
adrenergic, noradrenergic, histamine and glycine) or voltage-dependent
Ca
2+
, Na
+
or K
+
channels. In addition, it does not directly affect the acetylcholine
receptor or cholinergic
transmission, which have been implicated in the cholinomimetic side
effects (e.g., increased
gastric acid secretion, nausea and vomiting) seen with
acetylcholinesterase inhibitors.
Memantine showed antagonist effects at the 5HT
3
receptor with a potency similar to that for the
NMDA receptor.
PHARMACOKINETICS
ABSORPTION
Orally administered memantine is completely absorbed. Oral
bioavailability is almost 100%.
Time to maximum plasma concentration (t
max
) following single oral doses of 10